NOVAVAX, INC. 
By
Contacts: Barclay A. Phillips
Senior Vice President, Chief Financial Officer
Novavax, Inc.
240-268-2000
David Schull or Andrea Flynn, Ph.D. Russo Partners, LLC
212-845-4271
David.schull@russopartnersllc.com
Andrea.flynn@russopartnersllc.com
• Data are industry's first from clinical trial of vaccine against A(H7N9) strain of influenza
• 81% of 5ug adjuvanted vaccine recipients had protective HAI levels
• 97% of 5ug adjuvanted vaccine recipients had anti-neuraminidase antibody responses
• Protective levels achieved from vaccinations within 116 days of the announced outbreak of novel lethal H7N9 virus
• Dose-sparing formulation shows significant potential utility in the event of a pandemic
• Vaccine safety consistent with previously tested adjuvanted pandemic vaccines
Rockville, MD (November 13, 2013)-/GlobeNewswire, Inc./-Novavax, Inc. (NASDAQ: NVAX) today announced that positive clinical data for the company's virus-like particle (VLP) vaccine candidate against A(H7N9) influenza were published online in the Correspondence section of The New England Journal of Medicine. The correspondence can be found at: http://www.nejm.org/doi/full/10.1056/NEJMc1313186 and will appear in the December 26, 2013 print edition.
The study, conducted in 284 adult male and female subjects, examined the safety and immunogenicity of two administrations of Novavax' A(H7N9) VLP vaccine candidate on day 0 and day 21. Subjects were administered either placebo, 15 or 45 µg of vaccine alone, or 5 or
15µg of vaccine with either 30 or 60 ISCO® units of the saponin-based ISCOMATRIX® adjuvant, developed by CSL Limited in Australia. Serology was assessed at Days 0, 21 and 35 post-first immunization.
The Novavax A(H7N9) VLP vaccine candidate was generally well tolerated, and the safety was in line with the company's previous findings with its influenza VLP antigens using ISCOMATRIX® adjuvant. Overall, as with other adjuvanted influenza vaccines, there was an increase in transient local and systemic reactions in the adjuvanted in contrast to the non- adjuvanted formulations, but there were no treatment-related SAEs in the active groups. The A(H7N9) VLP vaccine candidate induced hemagglutination-inhibition (HAI) antibody titers of
